Macià Sureda-Vives

Mr. Macià Sureda-Vives

MRC London Institute of Medical Sciences
+1

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2020 in Thorax
Verified
Journal Article
Open access
PDF file
BFBarnaby Flower
Barnaby Flower
JBJonathan C Brown
Jonathan C Brown
BSBryony Simmons
Bryony Simmons
MMMaya Moshe
Maya Moshe
RFRebecca Frise
Rebecca Frise
GCGraham S Cooke
Graham S Cooke
Background Accurate antibody tests are essential to monitor the SARS-CoV-2 pandemic. Lateral flow immunoassays (LFIAs) can deliver testing at scale. However, reported performance varies, and sensitivity analyses have generally been conducted on serum from hospitalised patients. For use in community testing, evaluation of finger-prick self-tests, in non-hospitalised individuals, is required. Methods Sensitivity analysis was conducted on 276 non-hospitalised participants. All had tested positive for SARS-CoV-2 by reverse transcription PCR and were ≥21 days from symptom onset. In phase I, we evaluated five LFIAs in clinic (with finger prick) and laboratory (with blood and sera) in comparison to (1) PCR-confirmed infection and (2) presence of SARS-CoV-2 antibodies on two ‘in-house’ ELISAs. Specificity analysis was performed on 500 prepandemic sera. In phase II, six additional LFIAs were assessed with serum. Findings 95% (95% CI 92.2% to 97.3%) of the infected cohort had detectable antibodies on at least one ELISA. LFIA sensitivity was variable, but significantly inferior to ELISA in 8 out of 11 assessed. Of LFIAs assessed in both clinic and laboratory, finger-prick self-test sensitivity varied from 21% to 92% versus PCR-confirmed cases and from 22% to 96% versus composite ELISA positives. Concordance between finger-prick and serum testing was at best moderate (kappa 0.56) and, at worst, slight (kappa 0.13). All LFIAs had high specificity (97.2%–99.8%). Interpretation LFIA sensitivity and sample concordance is variable, highlighting the importance of evaluations in setting of intended use. This rigorous approach to LFIA evaluation identified a test with high specificity (98.6% (95%CI 97.1% to 99.4%)), moderate sensitivity (84.4% with finger prick (95% CI 70.5% to 93.5%)) and moderate concordance, suitable for seroprevalence surveys.

1 September 2017 in Clinical Biochemistry
Verified
Journal Article
Closed access
Macià Sureda-VivesMacià Sureda-Vives
Macià Sureda-Vives
DMDaniel Morell-Garcia
Daniel Morell-Garcia
ARAna Rubio-Alaejos
Ana Rubio-Alaejos
LVLaura Valiña
Laura Valiña
JRJuan Robles
Juan Robles
JBJosep Miquel Bauça
Josep Miquel Bauça

28 November 2020 in Life
Verified
Journal Article
Open access
PDF file
Macià Sureda-VivesMacià Sureda-Vives
Macià Sureda-Vives
KSKaren S Sarkisyan
Karen S Sarkisyan
Bioluminescence-based technologies are among the most commonly used methods to quantify and visualise physiology at the cellular and organismal levels. However, the potential of bioluminescence beyond reporter technologies remains largely unexplored. Here, we provide an overview of the emerging approaches employing bioluminescence as a biological light source that triggers physiological events and controls cell behaviour and discuss its possible future application in synthetic biology.